

### **Our Company**

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies.



> 53,000 employees worldwide



Founded in 1885 in Ingelheim and family-owned to this day

**Animal Health** 







**Biopharmaceutical** Contract Manufacturing

### **Successful Business Model**

**Human Pharma** 

18,461 million EUR net sales in 2022



Cardiometabolic





**Focus** 

system diseases

Respiratory

diseases

### Overall Financial Performance (2022)

**24,149** million EUR

19.8% Return on net sales

net sales

### **Americas**



11,470 million EUR



7,543 million EUR

Research & Development

Asia/Australia/ Africa (AAA)




5,136 million EUR

# Diversity, Equity & Inclusion (DEI) Drive Innovation

DEI is an integral part of Boehringer Ingelheim's identity. Through our core values of empathy, respect, passion and trust, we foster a diverse, collaborative, open and inclusive work environment, which is key for innovation, value creation and sustainable growth.

### All workforce - over 53,000 employees



50% Female



136 **Nationalities** 

### **Animal Health**

# 4,559 million EUR net sales in 2022



Share Livestock Companion



Pets



Cattle



Swine



Poultry



VPH 1 Equine

#### \*Veterinary Public Health (VPH)

## Build on our

principles

Our innovation guiding



Making More Health (MMH) is a global,

Ashoka (the world's largest network of

sustainable and holistic solutions to

animals and communities.

long-term initiative in collaboration with

social entrepreneurs) and works to create

today's healthcare challenges for people,

4,583 million EUR Human Pharma expenses in Research & Development in 2022

24.8%

of Human Pharma net sales 2022

### Supervisors - around 8.600 employees

gelheim worldwide, 2022

33% Generation Y (1981-2000)

9% **Baby Boomer** (1946-1964) 58%

> Generation X (1965-1980)

40% Female



**Nationalities** 

# **Biopharmaceutical Contract Manufacturing**

Boehringer Ingelheim BioXcellence™ is one of the world leaders in reliable supply of innovative therapies to improve patient health.

1.024 million EUR net sales in 2022

# We operate



global production network



to deliver technological expertise, process excellence, and superior quality.

We are a pioneer in biopharmaceuticals with over

35 years of experience.

We have manufactured 43

approved biopharmaceuticals used by patients all over the world.

# **Making More Health**



12 million

beneficiaries impacted

42 countries

125

active social entrepreneurs worldwide

11,000+

employees engaged